講演情報
[IL3]Alzheimer's Drug Development: Progress, Lessons, and Future Directions
Szofia S. Bullain
(Biogen International GmbH)
◆略歴
Dr. Szofia S. Bullain is a physician-scientist, drug development executive, and board-certified geriatric neurologist with more than two decades of experience spanning academia, clinical practice, and the biopharmaceutical industry. She currently serves as Vice President of Clinical Development at Biogen, where she oversees clinical development efforts within the Alzheimer's and Dementia Development Unit. Prior to joining Biogen in 2023, Dr. Bullain held several senior leadership roles in late-stage Alzheimer's disease drug development at F. Hoffmann–La Roche in Basel, Switzerland.
Before transitioning to industry, Dr. Bullain was a faculty member in the Department of Neurology at the University of California, Irvine (UCI) School of Medicine. She conducted clinical research at the UCI Alzheimer's Disease Research Center (ADRC) and served as an investigator for The 90+ Study, one of the world's leading longitudinal studies of aging and dementia in the oldest-old.
Originally from Budapest, Hungary, Dr. Bullain earned her Doctor of Medicine (MD) from Semmelweis University and a Diploma of Advanced Studies (DAS) in Pharmaceutical Medicine from the University of Basel. She completed a five-year translational neuroscience research fellowship at Harvard Medical School, followed by a neurology residency and a four-year fellowship in Geriatric Neurology at the University of California, Irvine.
Dr. Bullain's work focuses on the clinical development of therapies for Alzheimer's disease and related neurodegenerative disorders, drawing on her experience across academic research, clinical medicine, and pharmaceutical development.
(Biogen International GmbH)
◆略歴
Dr. Szofia S. Bullain is a physician-scientist, drug development executive, and board-certified geriatric neurologist with more than two decades of experience spanning academia, clinical practice, and the biopharmaceutical industry. She currently serves as Vice President of Clinical Development at Biogen, where she oversees clinical development efforts within the Alzheimer's and Dementia Development Unit. Prior to joining Biogen in 2023, Dr. Bullain held several senior leadership roles in late-stage Alzheimer's disease drug development at F. Hoffmann–La Roche in Basel, Switzerland.
Before transitioning to industry, Dr. Bullain was a faculty member in the Department of Neurology at the University of California, Irvine (UCI) School of Medicine. She conducted clinical research at the UCI Alzheimer's Disease Research Center (ADRC) and served as an investigator for The 90+ Study, one of the world's leading longitudinal studies of aging and dementia in the oldest-old.
Originally from Budapest, Hungary, Dr. Bullain earned her Doctor of Medicine (MD) from Semmelweis University and a Diploma of Advanced Studies (DAS) in Pharmaceutical Medicine from the University of Basel. She completed a five-year translational neuroscience research fellowship at Harvard Medical School, followed by a neurology residency and a four-year fellowship in Geriatric Neurology at the University of California, Irvine.
Dr. Bullain's work focuses on the clinical development of therapies for Alzheimer's disease and related neurodegenerative disorders, drawing on her experience across academic research, clinical medicine, and pharmaceutical development.
閲覧にはパスワードが必要です
抄録の閲覧には、パスワードが必要です。
※パスワードの確認方法※
・プログラム・抄録集のP.11
・参加登録システム（メディカルプライム）にログイン
（※決済完了後、緑帯の下に表示されます）
※パスワードの確認方法※
・プログラム・抄録集のP.11
・参加登録システム（メディカルプライム）にログイン
（※決済完了後、緑帯の下に表示されます）